MALAT1 and hepatocellular carcinoma: The existence of the MALAT1/miR-140-5p/AURKA axis highlights its potential as a therapeutic target in addressing sorafenib resistance in HCC management; indeed, its inhibition enhanced sorafenib efficacy in a nude mice model (Figure 2) [104].